Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy

Stephen A. Klassen, Jonathon W. Senefeld, Patrick W. Johnson, Rickey E. Carter, Chad C. Wiggins, Shmuel Shoham, Brenda J. Grossman, Jeffrey P. Henderson, James Musser, Eric Salazar, William R. Hartman, Nicole M. Bouvier, Sean T.H. Liu, Liise Anne Pirofski, Sarah E. Baker, Noud van Helmond, R. Scott Wright, Delisa Fairweather, Katelyn A. Bruno, Zhen WangNigel S. Paneth, Arturo Casadevall, Michael J. Joyner

Research output: Contribution to journalArticlepeer-review


To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from randomized clinical trials (RCT), matched-control, case series, and case report studies. Random-effects analyses of RCT data demonstrated that hospitalized COVID-19 patients transfused with convalescent plasma exhibited a lower mortality rate compared to patients receiving standard treatments. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized COVID-19 patients.

Original languageEnglish (US)
JournalUnknown Journal
StatePublished - Oct 29 2020


  • Convalescent plasma
  • Coronavirus disease 2019 (COVID-19)
  • Meta-analysis
  • Passive antibody therapy
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy'. Together they form a unique fingerprint.

Cite this